FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165239502> ?p ?o ?g. }

• W3165239502 endingPage "369" @default.
• W3165239502 startingPage "369.1" @default.
• W3165239502 abstract "Background: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma development. However, the association of the use of biologic disease modifying anti-rheumatic drugs (bDMARDs) in patients with RA on lymphoma risk needs further evaluation. Objectives: Examine the effect of administration of bDMARDS on the incidence of lymphoma in an inception cohort of RA. Methods: We identified patients diagnosed with RA in any US Veterans Affairs (VA) facility from 1/1/2002 and 12/31/2018 using the Veteran’s Health Administration (VHA) databases. To be included, each patient was required to meet the following criteria: 1) 2+ RA diagnostic codes at least 7 days apart but no more than 365 days apart 2) a prescription for a conventional synthetic DMARD (csDMARD) within 90 days of the first RA diagnosis 3) One inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating they are a regular user of the VHA). We excluded patients for any of the following if they preceded the first RA diagnosis: 1) a prior single RA diagnostic code 2) a prescription for any DMARD medication 3) a concomitant diagnosis of another inflammatory arthritis (e.g. psoriatic arthropathy) 4) a diagnosis of lymphoma. Index date for the study is the date of the first qualifying RA diagnosis. Lymphoma diagnoses were identified through VHA records using the International Classification of Diseases-Oncology codes. Results: We identified 27,536 veterans with RA in the study period meeting the inclusion and exclusion criteria. Of these, 53% (n=14,705) were in the age range 60 to 80 years. The cohort was 89% male, 75.5% White, 13.7% African American. Over the study period, 1.2% (n=332) of the study population developed a lymphoma. Conclusion: Using the nationwide VHA we have identified a large inception cohort of patients with RA of whom 1.2% developed lymphoma over study follow-up. This data will be used in future analyses to produce estimates of the effect of biologic medications on lymphoma risk, adjusting for confounding by indication and other variables. Table 1. Baseline characteristics of the cohort based on bDMARD exposure status Characteristic bDMARD-naive (n= 19,095) bDMARD-exposed (n=8,441) Overall Lymphomas Age (years) 171 161 18-40 4 6 40-60 63 78 60-80 100 74 >80 4 3 Males 17,206 (90%) 7,270 (86%) Race White 14,150 (74%) 6,627 (76%) Black 2,674 (14%) 1,090 (13%) Asian 96 (0.5%) 46 (0.5%) Native American or Pacific Islander 371 (2%) 187 (2.2%) Missing 1,804 (9%) 491 (6%) Acknowledgements: The work in this abstract is supported by Investigator Award from the Rheumatology Research Foundation to Dr Singh. Disclosure of Interests: None declared" @default.
• W3165239502 created "2021-06-07" @default.
• W3165239502 creator A5000754711 @default.
• W3165239502 creator A5006204416 @default.
• W3165239502 creator A5016958524 @default.
• W3165239502 creator A5018188165 @default.
• W3165239502 creator A5040501217 @default.
• W3165239502 creator A5042724179 @default.
• W3165239502 creator A5057135919 @default.
• W3165239502 creator A5091141926 @default.
• W3165239502 date "2021-05-19" @default.
• W3165239502 modified "2023-10-14" @default.
• W3165239502 title "POS0287 USE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RELATION TO THE RISK OF LYMPHOMA: A COHORT STUDY OF US VETERANS WITH RHEUMATOID ARTHRITIS" @default.
• W3165239502 doi "https://doi.org/10.1136/annrheumdis-2021-eular.3395" @default.
• W3165239502 hasPublicationYear "2021" @default.
• W3165239502 type Work @default.
• W3165239502 sameAs 3165239502 @default.
• W3165239502 citedByCount "0" @default.
• W3165239502 crossrefType "journal-article" @default.
• W3165239502 hasAuthorship W3165239502A5000754711 @default.
• W3165239502 hasAuthorship W3165239502A5006204416 @default.
• W3165239502 hasAuthorship W3165239502A5016958524 @default.
• W3165239502 hasAuthorship W3165239502A5018188165 @default.
• W3165239502 hasAuthorship W3165239502A5040501217 @default.
• W3165239502 hasAuthorship W3165239502A5042724179 @default.
• W3165239502 hasAuthorship W3165239502A5057135919 @default.
• W3165239502 hasAuthorship W3165239502A5091141926 @default.
• W3165239502 hasBestOaLocation W31652395021 @default.
• W3165239502 hasConcept C120665830 @default.
• W3165239502 hasConcept C121332964 @default.
• W3165239502 hasConcept C126322002 @default.
• W3165239502 hasConcept C2426938 @default.
• W3165239502 hasConcept C2775969662 @default.
• W3165239502 hasConcept C2776260265 @default.
• W3165239502 hasConcept C2777575956 @default.
• W3165239502 hasConcept C2779338263 @default.
• W3165239502 hasConcept C2779384505 @default.
• W3165239502 hasConcept C2908647359 @default.
• W3165239502 hasConcept C45827449 @default.
• W3165239502 hasConcept C61511704 @default.
• W3165239502 hasConcept C71924100 @default.
• W3165239502 hasConcept C72563966 @default.
• W3165239502 hasConcept C98274493 @default.
• W3165239502 hasConcept C99454951 @default.
• W3165239502 hasConceptScore W3165239502C120665830 @default.
• W3165239502 hasConceptScore W3165239502C121332964 @default.
• W3165239502 hasConceptScore W3165239502C126322002 @default.
• W3165239502 hasConceptScore W3165239502C2426938 @default.
• W3165239502 hasConceptScore W3165239502C2775969662 @default.
• W3165239502 hasConceptScore W3165239502C2776260265 @default.
• W3165239502 hasConceptScore W3165239502C2777575956 @default.
• W3165239502 hasConceptScore W3165239502C2779338263 @default.
• W3165239502 hasConceptScore W3165239502C2779384505 @default.
• W3165239502 hasConceptScore W3165239502C2908647359 @default.
• W3165239502 hasConceptScore W3165239502C45827449 @default.
• W3165239502 hasConceptScore W3165239502C61511704 @default.
• W3165239502 hasConceptScore W3165239502C71924100 @default.
• W3165239502 hasConceptScore W3165239502C72563966 @default.
• W3165239502 hasConceptScore W3165239502C98274493 @default.
• W3165239502 hasConceptScore W3165239502C99454951 @default.
• W3165239502 hasIssue "Suppl 1" @default.
• W3165239502 hasLocation W31652395021 @default.
• W3165239502 hasOpenAccess W3165239502 @default.
• W3165239502 hasPrimaryLocation W31652395021 @default.
• W3165239502 hasRelatedWork W1917853059 @default.
• W3165239502 hasRelatedWork W1994703157 @default.
• W3165239502 hasRelatedWork W2409856569 @default.
• W3165239502 hasRelatedWork W2519792912 @default.
• W3165239502 hasRelatedWork W2551236132 @default.
• W3165239502 hasRelatedWork W2810108657 @default.
• W3165239502 hasRelatedWork W2979236457 @default.
• W3165239502 hasRelatedWork W3158270843 @default.
• W3165239502 hasRelatedWork W3164831646 @default.
• W3165239502 hasRelatedWork W4312086935 @default.
• W3165239502 hasVolume "80" @default.
• W3165239502 isParatext "false" @default.
• W3165239502 isRetracted "false" @default.
• W3165239502 magId "3165239502" @default.
• W3165239502 workType "article" @default.